As pipelines diversify and new conjugation approaches emerge, facilities designed around today’s processes must be prepared ...

The distinctive properties of USP's mAb reference standards show utility for qualifying and monitoring methods for thermal ...

During our conversation, Seyf discussed his company’s involvement in the Australian ecosystem and how Australia is expanding ...

The physics that dictate this field’s timelines remain unforgiving. Radiopharmaceuticals cannot be inventoried the way ...

Connecting existing downstream steps delivers the value of continuous bioprocessing, says executive Jon Coffman at BioProcess ...

Reformatting historical data and getting scientists to agree on how to generate it are among the biggest hurdles in hybrid ...

Autolomous CEO Alexander Seyf explains why collaboration, not competition, could unlock progress in cell and gene therapy ...

NIBRT and San Jacinto College's biotech center in Houston train students for in-demand biomanufacturing and cell and gene therapy careers.

Ultimately, the discussion suggested that progress will come not from replacing CHO wholesale, but from pairing earlier, ...

Kevin Brower, global head of Purification Development at Sanofi, told delegates at the BioProcess International (BPI) conference last week that cost of goods reduction, sustainability, and lower ...

For decades, manufacturing pipelines have been dominated almost exclusively by traditional recombinant proteins and monoclonal antibodies (mAbs). Now, they are rapidly filling up with high-titer cell ...

Rationalizing Biological Drug Development: Biosimilar Science, Modality-Specific Pathways, and the Bioprocessing Revolution, Part 1 Regulatory frameworks for biosimilars were developed two decades ago ...